The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients

The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients Applying to Community Mental Health Center on Alexithymia and Emotion Expression

As a result of the positive and negative symptoms that occur in schizophrenia, patients with schizophrenia may experience negative emotions more frequently than individuals with other mental problems. Since these emotions can trigger psychotic symptoms, there is a need to develop effective emotion regulation strategies to be applied to patients with schizophrenia.

Aim: In this study, it was aimed to examine the effect of emotion recognition and expression program on alexithymia and emotion expression in patients with schizophrenia.

Study Overview

• Status: Completed
• Conditions: Schizophrenia; Alexithymia; Emotion, Expressed
• Intervention / Treatment: Behavioral: Emotions Recognition and Expression

Detailed Description

Method: Fifty schizophrenic patients who regularly receive outpatient treatment at Sinop Community Mental Health Center will form the universe of the study. Individuals over the age of 18 who have schizophrenia, do not have mental retardation, have no comprehension and hearing problems, have insight, and are in remission will be included in the study. Individuals who meet the study criteria will be divided into experimental and control groups as 22 experimental and 22 control groups. The emotion recognition and expression program prepared by the researchers in line with the literature will be applied to the experimental group for 8 weeks. Personal Information Form, Expression of Emotions Scale, Positive and Negative Syndrome Scale and Toronto Alexithymia Scale were planned to be applied to the experimental and control groups in the pre-test, post-test and follow-up. Follow-up will take place one month after the last session of the study. Psychosocial interventions applied to patients with schizophrenia help patients to increase their level of well-being and quality of life, to decrease negative and positive symptoms by increasing social functionality, to participate in social life, to be an autonomous individual and to prevent stigma. In line with psychosocial interventions, it is thought that the this program to be applied to the patients in this study will basically contribute to the individual patients' ability to recognize their emotions, discuss their emotions, regulate their emotion intensities, and express their emotions. Due to the impact that this program will have on the individual, it is believed that it will have positive results not only for schizophrenia patients, but also for the individuals with whom the patients interact, their relatives and even the society.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Sinop, Turkey, 57000
    • Sinop Community Mental Health Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient who had received a diagnosis of schizophrenia and comes to the Community Mental Health Center regularly,
• Being able to read and communicate
• Being 18 years of age or older,
• Not having mental retardation,
• Not having insight, understanding, hearing problems,
• Being in remission,
• Volunteering to study

Exclusion Criteria:

• Not diagnosed with clinical schizophrenia,
• Being under the age of 18,
• Having mental retardation,
• Having no insight,
• Not understanding and hearing,
• Not in remission
• Refusing to participate in the study
• Stop studying at any stage of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control group; At the beginning of the study, data collection tools Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the control group. No intervention will be made in the control group. Measurement tools will be applied for the posttest. Emotional Expression Scale, Toronto Alexithymia Scale and Positive and Negative Syndrome Scale will be reapplied 1 month after the last session.
Experimental: Experimental group; Emotion recognition and expression program is aimed to be carried out in 8-week sessions for schizophrenia patients included in the experimental group. Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the experiment. The principal investigator will lead the structured group sessions as the group leader. The principal investigator will lead the structured group sessions as the group leader. Each group is planned to be 60-90 minutes. Before sessions, participants are taken from their previous session's emotions so far. Homework is discussed by providing recall of the topic from the previous session, and then the current topic is moved on. At the end of each session, a general summary and evaluation is made. After the sessions in the research, measurement tools will be applied for the posttest. It will be reapplied 1 month after the last session.	Behavioral: Emotions Recognition and Expression; Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Emotion Recognition and Expression	Expression of Emotions Scale is used to measure the state of expression of emotions. The scale was developed by King and Emmons (1990), and its Turkish validity and reliability were verified by Kuzucu (2011). The measurement tool consists of a total of 16 items and 3 sub-dimensions. It has positive, negative and closeness sub-dimensions. It is a 7-point Likert type scale .The scores to be taken from the scale vary between 15 and 105, and as the scores obtained increase, it is seen that the tendency of the individual to express emotion increases. The scale provides information about expressing emotions both in interpersonal relationships and independent of interpersonal relationships. A high score indicates a high tendency to express emotions.	One day
Alexithymia	Toronto Alexithymia Scale (TAS): The scale was developed by Bagby et al. (1994) Güleç et al. (2009) adapted into Turkish. The scale consists of 20 items, has three sub-dimensions and is in a 5-point Likert type. High scores indicate high alexithymic level. There are sub-dimensions of difficulty in recognizing emotions, difficulty in putting emotions into words, and extroverted thinking.	One day
Positive and Negative Syndrome	Positive and Negative Syndrome Scale (PANNS): The scale evaluating positive and negative symptoms in schizophrenia was developed by Kay et al (1987) and Kostakoğlu et al. It was adapted into Turkish by (1999). Consisting of 30 items, the scale has three sub-dimensions. A 7-point severity assessment is carried out. Seven of the items of the scale belong to the positive symptoms subscale, seven to the negative symptoms subscale, and the remaining sixteen to the general psychopathology subscale.	One day

Collaborators and Investigators

• Sponsor: Sinop University
• Investigators: Principal Investigator: Adeviye AYDIN, PhD, Sinop University

Study record dates

Study Major Dates

• Study Start (Actual): January 15, 2023
• Primary Completion (Actual): May 15, 2023
• Study Completion (Actual): May 15, 2023

Study Registration Dates

• First Submitted: December 14, 2022
• First Submitted That Met QC Criteria: December 14, 2022
• First Posted (Actual): December 22, 2022

Study Record Updates

• Last Update Posted (Actual): October 31, 2023
• Last Update Submitted That Met QC Criteria: October 29, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Schizophrenia; Alexithymia; Emotion, Expressed
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Affective Symptoms
• Other Study ID Numbers: sınopUadeviye-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No